设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2024 年第 6 期 第 0 卷

枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征效果和安全性的Meta分析

Meta-analysis of the efficacy and safety of live combined bacillus subtilis enteric-coated capsules in the treatment of irritable bowel syndrome

作者:魏启鲁1张双2张向荣2张俊海3张艳丽1杜时雨1

英文作者:Wei Qilu1 Zhang Shuang2 Zhang Xiangrong2 Zhang Junhai3 Zhang Yanli1 Du Shiyu1

单位:1中日友好医院消化科,北京100029;2北京中医药大学,北京100029;3北京大学医学部,北京100191

英文单位:1Department of Gastroenterology China-Japan Friendship Hospital Beijing 100029 China; 2Beijing University of Chinese Medicine Beijing 100029 China; 3Peking University Health Science Center Beijing 100191 China

关键词:肠易激综合征;枯草杆菌二联活菌肠溶胶囊;Meta分析

英文关键词:Irritablebowelsyndrome;Livecombinedbacillussubtilisenteric-coatedcapsules;Meta-analysis

  • 摘要:
  • 目的 采用Meta分析方法评价枯草杆菌二联活菌肠溶胶囊治疗肠易激综合征(IBS)的效果及安全性。方法 系统检索了PubMed、Embase、中国生物医学文献、中国知网、万方、维普、Cochrane Library等数据库,检索时间截止至2023年6月。观察组采用枯草杆菌二联活菌肠溶胶囊单用或联合其他药物治疗,对照组采用其他药物单药或联合治疗。利用RevMan 5.4.1软件进行Meta分析。结果 Meta分析结果显示,观察组总有效率优于对照组(相对危险度=1.20,P<0.001),腹痛、腹泻症状发生率均低于对照组(均P<0.05),而2组不良反应发生率差异无统计学意义(比值比=0.80,P=0.28)。亚组分析结果显示,观察组腹泻型IBS和便秘型IBS患者的治疗总有效率均高于对照组(均P<0.05)。结论 基于目前的文献证据,枯草杆菌二联活菌肠溶胶囊治疗IBS有效性及安全性均较好。

  • Objective To evaluate the efficacy and safety of live combined bacillus subtilis enteric-coated capsules in the treatment of irritable bowel syndrome (IBS) by Meta-analysis. Methods PubMed, Embase, CBM, CNKI, Wanfang, VIP, Cochrane Library and other databases were systematically searched until June 2023. The observation group was treated with live combined bacillus subtilis enteric-coated capsules alone or combined with other drugs, and the control group was treated with other drugs alone or combined. RevMan 5.4.1 software was used for Meta-analysis. Results Meta-analysis showed that the total effective rate of the observation group was better than that of the control group (relative risk=1.20, P<0.001), and the incidences of abdominal pain and diarrhea symptoms were lower than those of the control group (all P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups (odds ratio=0.80, P=0.28). Subgroup analysis showed that the total effective rates of the observation group were higher than those of the control group in diarrhea-predominant IBS and constipation-predominant IBS (both P<0.05). Conclusion Based on the current literature evidence, live combined bacillus subtilis enteric-coated capsules are effective and safe in the treatment of IBS.

copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map